Roche Holding AG (RHHBY)
| Market Cap | 284.18B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 23.97 |
| Forward PE | 13.73 |
| Dividend | 0.87 (2.13%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 69,983 |
| Average Volume | 1,345,021 |
| Open | 40.96 |
| Previous Close | 41.15 |
| Day's Range | 40.96 - 41.62 |
| 52-Week Range | 34.10 - 44.31 |
| Beta | 0.18 |
| RSI | 51.29 |
| Earnings Date | Oct 20, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Bullish (NYSE: BLSH) rose sharply in pre-market trading after the company posted a profit for the second quarter after Wednesday's closing bell. Bullish reported quarterly earnings of 93 ce...
Roche (OTCQX:RHHBY) to Acquire 89bio (ETNB) in $2.4 Billion Deal
Roche (OTCQX:RHHBY) to Acquire 89bio (ETNB) in $2.4 Billion Deal
89bio To Be Bought By Roche For Around $3.5 Bln
(RTTNews) - 89bio, Inc. (ETNB), which develops therapies for liver and ardiometabolic diseases said that it has inked a deal to be acquired by Roche Holding AG (RHHBY) for $14.50 per share in cash, or...
Roche to acquire 89bio in deal worth up to $3.5 billion
Roche to Buy 89bio for Up to $3.5 Billion
The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity comorbidity.
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Basel, 18 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-s...
Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level?
Denmark has Novo Nordisk, France has Sanofi, Switzerland boasts both Roche and Novartis, while Germany has Bayer. Its a somewhat troubled relationship, but Britain has AstraZeneca.
Roche Holding Integrates Its Continuous Glucose Monitoring Solution With MySugr App
(RTTNews) - Roche Holding AG (RHHBY.PK), Tuesday announced the integration of Accu-Chek SmartGuide's AI-enabled predictive continuous glucose monitoring solution with the mySugr diabetes management ap...
Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience
The integration of Accu-Chek SmartGuide's AI-enabled predictive CGM with the popular mySugr app delivers a simple, intuitive solution for people to manage their diabetes with greater ease. Accu-Chek S...
The Zacks Analyst Blog Highlights Roche, Linde, Disney and Vaso
Zacks spotlights Roche, Linde, Disney, and Vaso as analysts weigh drug demand, gas contracts, global expansion, and IT-driven resilience.
Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug
Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar...
Henlius Biotech in talks with J&J, Roche on cancer drug: report
Shanghai Henlius may sell rights to cancer drug HLX43 to J&J or Roche, with a deal worth hundreds of millions.
Top Analyst Reports for Roche, Linde & Walt Disney
Roche gains from strong drug demand, Linde builds on record orders, while Disney faces TV woes and bets on global growth.
Roche Holding AG (RHHBY) Presents at Goldman Sachs 22nd European Medtech & Healthcare Services Conference - Slideshow
The following slide deck was published by Roche Holding AG in conjunction with this event.
Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news
Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or ...
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or âwetâ age-related macular degeneration (nAMD) | RHHBY Stock News
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify ...
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients | RHHBY Stock News
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The V...
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 05 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab),1,2 presented at the 25th Euretina Congress in Pa...
New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricim...
Roche gets EU CE mark for its Port Delivery platform containing Susvimo
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
Basel, 04 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the EU CE mark for its Port Delivery Platform containing Susvimo, which will now be known as Contivue...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Three Dividend Funds with Foreign Flair
This month's trio includes an unofficial dividend aristocrat.